ProMIS Neurosciences Appoints Ivana Rubino as Chief Commercial Officer

Key Facts

1ProMIS Neurosciences appointed Dr. Ivana Rubino, a former Biogen executive, as its new Chief Commercial Officer.

2Rubino will lead the commercial strategy for Alzheimer's drug PMN310 ahead of Phase 1b results expected in Q1 2027.

ProMIS Neurosciences appointed Dr. Ivana Rubino, a former Biogen executive, as its new Chief Commercial Officer. StreetInsider reported that Rubino will lead the commercial strategy for PMN310, the company's Alzheimer's drug candidate, ahead of Phase 1b results expected in the first quarter of 2027.

PMN closed at $9.37 on October 5, 2026, while shares of Biogen (BIIB), where Rubino previously served, closed at $223.59 on the same date. The appointment strengthens the company's leadership team as it prepares for market entry and key clinical milestones for its lead neuroscience candidate.